NEW YORK (GenomeWeb News) – Agendia, AstraZeneca, and the Netherlands Cancer Institute today announced a collaboration to identify specific molecular subtypes of colorectal cancer in order to develop targeted therapies.
As part of the deal, Agendia will provide molecular data, bioinformatics support, and diagnostics expertise to AstraZeneca to define subpopulations within colorectal cancer, which kills about 500,000 people in the US and Europe each year, the partners said.
Further terms of the deal were not disclosed.
Bernard Sixt, CEO and co-founder of Agendia, said in a statement that the collaboration will benefit both direct participants as well as the scientific community by "providing a much greater understanding of the various disease types in the colorectal field." He added that a key feature of the partnership is that it may enable the development of companion diagnostics far more quickly than has been currently possible.
Rene Bernards, professor of molecular carcinogenesis at NKI and co-founder of Agendia, said that he and his colleagues have identified distinct molecular subtypes in colorectal cancer, each responding differently to different therapies. "Along with our new partners, we aim to identify drivers of the oncogenic process in each of these subtypes."